Condition
Piebaldism
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
100%
4 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 3 (1)
P 4 (3)
Trial Status
Completed2
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02156427Phase 3Completed
Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism
NCT02458417Phase 4Completed
Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients
NCT01640678Phase 4UnknownPrimary
Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients
NCT01377077Phase 4Unknown
Punchgrafting Techniques for Vitiligo
Showing all 4 trials